Chemical | 18 January 2021
Smruthi Organics Q3FY21 PAT drops QoQ to Rs. 5.10 crore
The company has posted net profit of Rs.13.93 crores for the 9 months period ended December 31, 2020
The company has posted net profit of Rs.13.93 crores for the 9 months period ended December 31, 2020
The company has posted net profit of Rs.15.29 crores for the 9 months period ended December 31, 2020.
The Board of Directors has also appointed R. K. Jain as an Additional Director with effect from January 14, 2021.
This AI laboratory will be the first of its kind in Europe to apply AI to full-scale biomanufacturing from microbial strain development to process optimization and scheduling.
The joint venture will manufacture hydrogen at the refinery for use across the HyNet region.
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Hybrid electric vehicles to be supplied with below zero carbon intensity biofuel
The phase 3 clinical trial of Sputnik V will be conducted on 1,500 subjects as part of the randomized, double blind, parallel group placebo controlled study in India.
In the joint venture (JV), Aarvi Encon FZE would own 70 percent controlling stake and the local owner at Oman would own the balance 30 percent minority stake.
The company has recently been granted a patent for “Fabric and Method of Manufacturing Fabric" by the European Patent office.
The stock has delivered a whopping ~150% returns over the last one year and a large part of the rerating is attributed to greater visibility in the CRAMS segment.
The scope of the Fund’s investment activities covers Japan and Taiwan, and includes as yet unlisted drug discovery and regenerative medicine biotech startup companies, and candidate drugs developed by universities, research institutes, and private corporations
This branding change will allow Nobian to develop its integrated European value chain for essential base chemicals
LANXESS plans to finance the envisaged acquisition with an enterprise value of approximately EUR 70 million out of cash.
With the expansion, Avient will also improve lead times for color matching locally.
Huntsman paid $250 million, subject to customary closing adjustments, in an all-cash transaction funded from available liquidity.
Novasep's viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally," said Michel Lagarde, executive vice president, Thermo Fisher.
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
MCC has reviewed its business units, and in April of this year will reorganize and consolidate them in alignment with products and market sectors.
In FY 2020-2021 (upto 12th January 2021) Jan Aushadhi Kendras have completed sales of Rs. 484 crores at 7,064 Pradhan Mantri Bhartiya Jan Aushadhi Kendras
Subscribe To Our Newsletter & Stay Updated
_195_291.jpg)
